Information Provided By: 
Fly News Breaks for October 16, 2015
JAZZ
Oct 16, 2015 | 07:08 EDT
Northland analyst David Buck said the U.S. Patent and Trade Office's denial of an inter partes review of Jazz' patent related to Xyrem's distribution system, which was requested by a group linked to hedge fund manager Kyle Bass, is a moderate positive. Buck notes, however, that there are still a series of Xyrem patents under PTAB review, with a decision likely in the second half of next year. The analyst keeps an Outperform rating and $200 price target on Jazz Pharmaceuticals.
News For JAZZ From the Last 2 Days
There are no results for your query JAZZ
